Innunity Therapeutics is pioneering the development of first-in-class novel treatments for Multiple Sclerosis (MS) by targeting innate immunity, the silent driver of disease progression. Our focus is on the slow, chronic “smoldering” inflammation in the CNS which persists in patients even during remission or in progressive stages of MS. Current treatments fail to address this persistent inflammation, and patients experience irreversible neurodegeneration, leading to substantial loss of life productivity. By leveraging cutting-edge science, our small molecule therapy aims to provide solutions that address this unmet need in MS care. We are currently advancing our preclinical and business development, while seeking strategic partnerships to bring this innovative approach toward the clinic.
